540729
vs
B
BSE Sensex 30
540729
Over the past 12 months, VANTABIO has underperformed BSE Sensex 30, delivering a return of -32% compared to the BSE Sensex 30's +6% growth.
Stocks Performance
540729 vs BSE Sensex 30
Performance Gap
540729 vs BSE Sensex 30
Performance By Year
540729 vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vanta Bioscience Ltd
Glance View
Vanta Bioscience Ltd. engages in the full service preclinical contract research organization. The company is headquartered in Secunderabad, Telangana. The company went IPO on 2017-10-06. The firm is engaged in research and development in the field of discovery and development of drugs, biological, vaccines, gene-based therapies, as well as diagnostics and cosmetics, including clinical research. The company provides risk assessment services for evaluating the safety of the active pharmaceutical ingredients (API), excipients, extractable and leachable, including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. The company also provides expert services for determination of health-based exposure limits, such as permitted daily exposure (PDE) or allowable daily exposure (ADE), including occupational exposure limits (OEL) for pharmaceutical manufacturers. The firm's subsidiaries include Vanta Clinical Research Limited and Vayam Research Solutions Limited.
